Clinical Trials: Regulatory Audit Findings

Best Practices for Preventing CAPA-Related Audit Findings

Posted on digi By digi

Corrective and Preventive Action (CAPA) systems form the backbone of quality assurance in clinical trials. Regulators such as the FDA, EMA, and MHRA expect sponsors, CROs, and investigator sites to not only implement CAPA for audit findings but also to ensure sustainability and prevention of recurrence. Despite this, CAPA-related deficiencies remain one of the most common regulatory audit findings, highlighting weaknesses in root cause analysis, documentation, and oversight.

Click to read the full article.

CAPA & Inspection Readiness Audit Findings, Regulatory Audit Findings

Case Study: Top Audit Findings in Oncology Clinical Trials

Posted on digi By digi

Oncology clinical trials are among the most scrutinized by regulatory agencies such as the FDA, EMA, and MHRA. These studies typically involve vulnerable patient populations, complex investigational products, and high safety risks. Because of this, oncology trials frequently attract regulatory attention, and audit findings in this area highlight systemic weaknesses in trial design, execution, and oversight.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Lessons from EMA Audit Findings in Rare Disease Clinical Trials

Posted on digi By digi

Rare disease clinical trials present unique regulatory challenges due to small patient populations, complex trial designs, and ethical considerations. The European Medicines Agency (EMA) pays close attention to these studies, as even minor compliance issues can significantly impact data integrity and patient safety. Audit findings from EMA inspections often highlight systemic weaknesses in sponsor and CRO practices when managing rare disease trials.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Phase I Clinical Research Unit Audit Findings: Key Issues

Posted on digi By digi

Phase I clinical trials are the first-in-human studies that focus on assessing the safety, tolerability, and pharmacokinetics of investigational products. These early-stage studies are conducted in specialized Clinical Research Units (CRUs), where the integrity of processes and compliance with ICH GCP are critical to protecting participants and generating reliable data. Because of their importance, FDA, EMA, and MHRA inspections of Phase I units often reveal systemic deficiencies that highlight weaknesses in oversight and quality systems.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Phase II vs. Phase III Audit Observations Compared

Posted on digi By digi

Clinical trial audits evolve as studies progress from Phase II (exploratory) to Phase III (confirmatory) research. Regulatory authorities such as the FDA, EMA, and MHRA scrutinize each stage differently due to the trial’s purpose, sample size, and associated risks. Phase II trials often focus on proof-of-concept and dose optimization, while Phase III trials evaluate efficacy and safety in large populations. These differences directly influence the nature of audit findings and regulatory expectations.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Impact of Regulatory Audit Findings on Trial Timelines and Approvals

Posted on digi By digi

Regulatory audit findings are not simply compliance observations; they directly influence clinical trial timelines and marketing approval processes. Agencies such as the FDA, EMA, and MHRA evaluate compliance with ICH GCP and national legislation, and their findings can cause delays in data submission, trial continuation, and ultimately, drug approval. Sponsors and CROs must understand how findings escalate from site-level deficiencies to system-wide risks, leading to extended development cycles.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Audit Findings in Decentralized Clinical Trials: Common Issues

Posted on digi By digi

Decentralized Clinical Trials (DCTs) are reshaping clinical research by shifting trial activities from traditional investigator sites to patient-centric and technology-driven models. Features such as eConsent, remote monitoring, direct-to-patient IMP delivery, and telemedicine visits have introduced new compliance risks. Regulatory agencies like the FDA, EMA, and MHRA increasingly focus on how sponsors and CROs adapt their oversight and quality systems for DCTs.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Adaptive Design Trials: Audit Observations and Compliance Lessons

Posted on digi By digi

Adaptive design clinical trials introduce flexibility into trial conduct by allowing pre-planned modifications to the study based on interim analyses. While these designs improve efficiency, they also increase regulatory complexity. Agencies such as the FDA, EMA, and MHRA closely examine adaptive designs to ensure that modifications do not compromise patient safety, data integrity, or statistical validity.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

High-Profile Trial Suspensions Due to Audit Findings: What Went Wrong

Posted on digi By digi

Regulatory audits play a crucial role in ensuring that clinical trials comply with ICH GCP and national legislation. In some cases, deficiencies are so significant that regulators suspend or place studies on clinical hold until issues are resolved. Such high-profile suspensions attract attention because they delay product development, increase costs, and can damage the sponsor’s reputation.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings

Predicting Regulatory Audit Findings Using Risk Assessment Models

Posted on digi By digi

Regulatory inspections are traditionally reactive, highlighting compliance deficiencies after they occur. However, with increasing complexity in clinical trials, sponsors and CROs are turning to risk assessment models to proactively predict potential audit findings. Agencies such as the FDA, EMA, and MHRA encourage the use of risk-based approaches aligned with ICH E6(R2) and ICH Q9 (Quality Risk Management) to strengthen inspection readiness.

Click to read the full article.

Case Studies & Trends in Audit Findings, Regulatory Audit Findings